Owkin Dx

Both products are algorithms operating on slides the laboratory already produces, with no assay, reagent, scanner, or sequencing step of their own. That is the entire commercial thesis: extract prognostic and biomarker signal from routine H and E rather than from an additional molecular test. Remove the model and there is no product and no test.

Both products are structurally positioned to inform a clinician rather than replace a test, but they do so differently and the distinction matters. RlapsRisk BC produces a risk score used alongside clinico-pathological factors, explicitly as an additional layer of information rather than a standalone determination. MSIntuit CRC is a pre-screen that rules OUT microsatellite stable cases so pathologists concentrate confirmatory testing on the rest, which means a false negative removes a patient from confirmatory MSI testing entirely. A rule-out design placed upstream of confirmatory testing carries different risk than a flag placed alongside it, and buyers should understand which they are deploying.

Development and validation cohorts are disclosed with real specificity for RlapsRisk BC: more than 1,800 patients in training and validation on independent cohorts of more than 1,200 slides, conducted blind and single shot, which is a stronger methodological statement than most vendors make. Performance is reported as a concordance index, 0.81 for the AI score combined with clinico-pathological factors versus 0.76 for those factors alone, which quantifies the incremental contribution rather than the model's standalone accuracy. That framing is the honest one for an adjunct test. Architecture detail and per-subgroup performance are not published, and equivalent methodological detail for MSIntuit CRC was not located.

Genuine evidence with an important caveat the vendor itself discloses. RlapsRisk BC was developed with Gustave Roussy following a 2019 regional AI for Health challenge grant, with research presented at ESMO 2021 and USCAP 2022, and blind validation on independent cohorts exceeding 1,200 slides. The caveat, stated in the vendor's own footnote, is that the validation cohort contained patients treated with endocrine therapy only and was ENRICHED with patients who experienced metastatic relapse, which inflates apparent discrimination relative to an unselected screening population. Independent validation is underway through a partnership with Cerba Path across routine digital workflows. Conference presentations and enriched cohorts sit below the standard of the peer reviewed multi-cohort validations achieved by Stratipath and DoMore in adjacent indications.

No specific PHI handling or data governance framework was located for the diagnostics products. The parent company's federated learning heritage is relevant in principle, since federated approaches keep data at source, but no stewardship terms specific to these diagnostics were located.

No HIPAA or BAA commitment was located. Both products are CE-IVD marked for European diagnostic use rather than FDA cleared, so US clinical deployment is not the current route and the question is largely prospective.

No SOC 2, ISO 27001, or equivalent attestation and no trust center were located in the materials reviewed for the diagnostics line.

Two CE-IVD approvals granted September 2022, both reported as first in class in Europe: the first CE-IVD digital pathology AI predicting breast cancer relapse risk, and the first CE-IVD AI identifying microsatellite stable colorectal patients from routine histology. No FDA clearance was located. One detail a buyer should catch: independent survey work indexes RlapsRisk BC as CE-IVD General under the older IVDD directive rather than under IVDR, the same distinction flagged against Visiopharm's DeepBio-supplied prostate APP, and IVDD carries a materially lower evidence bar than IVDR. Graded C on the established basis of real European authorization without US clearance.

The vendor discloses its cohort enrichment openly, which is a form of honesty about validation limits that many competitors omit, and blind single shot validation on independent cohorts guards against overfitting. What is absent is demographic subgroup analysis, which carries specific weight here because the company markets RlapsRisk BC as levelling access to precision testing for patients who cannot reach gene expression testing. A tool justified on equity grounds should demonstrate it performs equitably, and that evidence was not located.

Delivery runs through pathology laboratory workflows rather than the EHR, with integration into routine digital pathology pipelines pursued via the Cerba Path partnership across that network's laboratories. No published connector list, scanner compatibility matrix, or platform integration detail equivalent to Primaa's multi-platform disclosure was located, so integration depth is asserted through partnership rather than enumerated.

No hosting, tenancy, or data residency terms were located for the diagnostics products.

No rates are published, but the commercial case is more legible than most because both products define themselves against a priced comparator. RlapsRisk BC is positioned against gene expression tests the company describes as expensive and not always accessible, and MSIntuit CRC against the volume of confirmatory MSI testing it displaces. In both cases a buyer can model value against a known line item, the cost of the molecular test avoided or deferred, rather than against an abstract efficiency claim. That is the same reasoning applied to Stratipath.

Two indications, each narrowly specified: ER positive HER2 negative early invasive breast cancer post surgery for relapse risk, and colorectal cancer for MSI pre-screening. Both are high volume decisions where the alternative is expensive molecular testing, which is a coherent strategy rather than scattered coverage. But scope is confined to those two tumour types and, for the breast product, to one receptor subtype and one treatment context. The company states intent to expand biomarker pre-screening and outcome prediction across further disease areas.